A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were not at their low-density lipoprotein (LDL-C) goal (as per the National Cholesterol Education Program Adult Treatment Panel III guidelines) and in those with low high-density lipoprotein cholesterol (HDL-C). Patients on a stable dose of statin ± other lipid-modifying therapies and with LDL-C ≥70 to <115, ≥100 to <145, ≥130, or ≥160 mg/dl for very high, high, moderate, or low CHD risk or at LDL-C goal (per CHD risk category) with HDL-C ≤40 mg/dl were randomized in a ratio of 1:1 to anacetrapib 100 mg (n = 290) or placebo (n = 293) for 24 weeks, followed by a 12-week off-drug phase. The co-primary end points were % change from baseline in LDL-C and HDL-C and the safety profile of anacetrapib. Treatment with anacetrapib reduced LDL-C (BQ) by 37% (95% confidence interval -42.5, -31.0) and increased HDL-C by 118% (95% confidence interval 110.6, 125.7) relative to placebo (p <0.001 for both). Anacetrapib also reduced non-HDL-C, apolipoprotein B, and lipoprotein a and increased apolipoprotein AI versus placebo (p <0.001 for all). There were no clinically meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes, creatine kinase, blood pressure, electrolytes, or adjudicated cardiovascular events. Treatment with anacetrapib substantially reduced LDL-C and also increased HDL-C and was well tolerated over 24 weeks in statin-treated patients with hypercholesterolemia or low HDL-C.

Seguimiento de un grupo de pacientes con desfibrilador automßtico implantable / Follow-up of a group of patients with automatic implantable defibrillator

The automatic implantable defibrillator (AID) is the treatment of choice for primary and secondary prevention of sudden death. At the Instituto Nacional de CardiologÝa, since October 1996 until January 2002, 25 patients were implanted with 26 AID. There were 23 men (92) and the mean age of the whole group, was 51.4 years. Twenty-three patients (92) presented structural heart disease, the most common was ischemic heart disease in 13 patients (52), with a mean ejection fraction of 37.8. One patient without structural heart disease had Brugada Syndrome. The most frequent clinical arrhythmia was ventricular tachycardia in 14 patients (56). The mean follow-up was of 29.3 months during which a total of 30 events of ventricular arrhythmia were treated through AID; six of them were inappropriate due to paroxismal atrial fibrillation; 10 AID patients (34) have not applied for therapy. Three patients (12) of the group died due to congestive heart failure refractory to pharmacologic treatment. CONCLUSION: The implant of the AID is a safe and effective measure for primary and secondary prevention of sudden death. World-wide experience evidences, that this kind of device has not modified the mortality rate due to heart failure in these patients, but it has diminished sudden arrhythmic death.

Cardioversión interna de la fibrilación auricular crónica / Internal cardioversion in chronic atrial fibrillation

The importance of atrial fibrillation has always motivated the search of new treatment alternatives. Internal cardioversion has been proposed as a choice in the treatment of atrial fibrillation, giving rise to the development of atrial defibrillator. We present the case of a 68 years old patient without structural heart disease and with diagnosis of chronic atrial fibrillation of 10 months of evolution. He received treatment with antiarrhythmic drugs and successful electrical external cardioversion, but he relapsed a week later. For this reason, we decided to perform internal cardioversion with an electrocatheter (DAIG) placed in the coronary sinus through the right jugular vein and under light sedation with propofol (2 mg/kg weight). We applied three shocks of 1, 3, and 5 joules, being able to convert to sinus rhythm without complications. The patient continues under treatment with antiarrhythmic agents. Internal cardioversion has shown to be an effective way for the treatment of chronic atrial fibrillation, using a light sedation and low energy level to reestablish the sinus rhythm.